0.459
price down icon2.28%   -0.0107
after-market Dopo l'orario di chiusura: .46 0.001 +0.22%
loading
Precedente Chiudi:
$0.4697
Aprire:
$0.46
Volume 24 ore:
610.52K
Relative Volume:
1.28
Capitalizzazione di mercato:
$39.49M
Reddito:
$2.24M
Utile/perdita netta:
$-136.67M
Rapporto P/E:
-0.2004
EPS:
-2.29
Flusso di cassa netto:
$-102.08M
1 W Prestazione:
-16.30%
1M Prestazione:
-25.23%
6M Prestazione:
-69.60%
1 anno Prestazione:
-87.59%
Intervallo 1D:
Value
$0.421
$0.4844
Intervallo di 1 settimana:
Value
$0.421
$0.5583
Portata 52W:
Value
$0.421
$4.4278

Century Therapeutics Inc Stock (IPSC) Company Profile

Name
Nome
Century Therapeutics Inc
Name
Telefono
215-981-4000
Name
Indirizzo
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Name
Dipendente
0
Name
Cinguettio
Name
Prossima data di guadagno
2025-03-19
Name
Ultimi documenti SEC
Name
IPSC's Discussions on Twitter

Confronta IPSC con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
IPSC
Century Therapeutics Inc
0.459 39.49M 2.24M -136.67M -102.08M -2.29
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.01 124.29B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.64 66.76B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
590.06 35.99B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
262.16 33.93B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
264.32 28.47B 3.81B -644.79M -669.77M -6.24

Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-08-08 Iniziato Rodman & Renshaw Buy
2023-08-28 Downgrade JP Morgan Overweight → Neutral
2022-12-27 Iniziato Chardan Capital Markets Buy
2022-10-31 Iniziato Guggenheim Buy
2022-10-10 Iniziato Canaccord Genuity Buy
2022-05-23 Iniziato H.C. Wainwright Buy
2022-05-12 Iniziato William Blair Mkt Perform
2021-07-13 Iniziato BofA Securities Buy
2021-07-13 Iniziato JP Morgan Overweight
2021-07-13 Iniziato Piper Sandler Overweight
Mostra tutto

Century Therapeutics Inc Borsa (IPSC) Ultime notizie

pulisher
07:36 AM

H.C. Wainwright cuts Century Therapeutics target to $2 By Investing.com - Investing.com UK

07:36 AM
pulisher
03:34 AM

American Century Companies Inc. Raises Position in Denali Therapeutics Inc. (NASDAQ:DNLI) - Defense World

03:34 AM
pulisher
Mar 30, 2025

Guggenheim Reiterates Buy Rating for Century Therapeutics (NASDAQ:IPSC) - Defense World

Mar 30, 2025
pulisher
Mar 28, 2025

What is Chardan Capital’s Estimate for IPSC FY2025 Earnings? - Defense World

Mar 28, 2025
pulisher
Mar 25, 2025

Century Therapeutics (IPSC) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

Mar 25, 2025
pulisher
Mar 25, 2025

Century Therapeutics (NASDAQ:IPSC) Price Target Lowered to $7.00 at Chardan Capital - Defense World

Mar 25, 2025
pulisher
Mar 25, 2025

William Blair Issues Optimistic Forecast for IPSC Earnings - The AM Reporter

Mar 25, 2025
pulisher
Mar 24, 2025

Carnival To Rally Around 48%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga

Mar 24, 2025
pulisher
Mar 24, 2025

Q1 EPS Estimate for Century Therapeutics Boosted by Analyst - Defense World

Mar 24, 2025
pulisher
Mar 24, 2025

Chardan Cuts Price Target on Century Therapeutics to $7 From $11, Keeps Buy Rating - MarketScreener

Mar 24, 2025
pulisher
Mar 23, 2025

Century Therapeutics Announces Strategic Pipeline Shift and 2024 Financial Results - MSN

Mar 23, 2025
pulisher
Mar 23, 2025

Guggenheim Lowers Century Therapeutics (NASDAQ:IPSC) Price Target to $5.00 - Defense World

Mar 23, 2025
pulisher
Mar 23, 2025

Piper Sandler Cuts Century Therapeutics (NASDAQ:IPSC) Price Target to $2.00 - Defense World

Mar 23, 2025
pulisher
Mar 22, 2025

Guggenheim cuts Century Therapeutics target to $5, keeps Buy rating By Investing.com - Investing.com Canada

Mar 22, 2025
pulisher
Mar 22, 2025

What is William Blair’s Estimate for IPSC Q3 Earnings? - Defense World

Mar 22, 2025
pulisher
Mar 21, 2025

Demystifying Century Therapeutics: Insights From 4 Analyst Reviews - Benzinga

Mar 21, 2025
pulisher
Mar 20, 2025

Century Therapeutics Reports 2024 Financial Results and Strategic Updates - TipRanks

Mar 20, 2025
pulisher
Mar 20, 2025

Leerink Partners Adjusts Price Target on Century Therapeutics to $8 From $13, Keeps Outperform Rating - Marketscreener.com

Mar 20, 2025
pulisher
Mar 19, 2025

Century Therapeutics, Inc. (IPSC) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance

Mar 19, 2025
pulisher
Mar 19, 2025

Century Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 19, 2025
pulisher
Mar 19, 2025

Century Therapeutics Announces Pipeline Re-Prioritization to Focus on Transformational Programs and Extends Cash Runway into Q4 2026 - Nasdaq

Mar 19, 2025
pulisher
Mar 19, 2025

Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire

Mar 19, 2025
pulisher
Mar 19, 2025

Century Therapeutics Secures 2-Year Cash Runway with $220M War Chest - StockTitan

Mar 19, 2025
pulisher
Mar 16, 2025

Brokerages Set Century Therapeutics, Inc. (NASDAQ:IPSC) Price Target at $10.00 - Defense World

Mar 16, 2025
pulisher
Mar 13, 2025

Century therapeutics officer sells shares worth $1,451 By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 13, 2025

Century Therapeutics SVP sells $762 in stock By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 12, 2025

Century therapeutics CEO sells shares to cover tax obligations By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 12, 2025

Century therapeutics CEO sells shares to cover tax obligations - Investing.com

Mar 12, 2025
pulisher
Mar 12, 2025

Century Therapeutics COO Farid Adrienne sells $1,450 in stock - Investing.com India

Mar 12, 2025
pulisher
Mar 12, 2025

Century therapeutics officer sells shares worth $1,451 - Investing.com

Mar 12, 2025
pulisher
Mar 12, 2025

Century Therapeutics SVP sells $762 in stock - Investing.com

Mar 12, 2025
pulisher
Mar 12, 2025

Century Therapeutics COO Farid Adrienne sells $1,450 in stock By Investing.com - Investing.com UK

Mar 12, 2025
pulisher
Mar 11, 2025

Verrica Pharmaceuticals Inc. (VRCA) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance

Mar 11, 2025
pulisher
Mar 07, 2025

Layoff Tracker: Atea Pharmaceuticals Cuts 25% of Workforce - BioSpace

Mar 07, 2025
pulisher
Mar 06, 2025

Century Therapeutics (IPSC) Expected to Announce Quarterly Earnings on Thursday - Defense World

Mar 06, 2025
pulisher
Mar 05, 2025

CAR T-cell Therapy Clinical Trial Pipeline Experiences - GlobeNewswire

Mar 05, 2025
pulisher
Mar 05, 2025

CAR T-cell Therapy Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain - GlobeNewswire Inc.

Mar 05, 2025
pulisher
Mar 01, 2025

Century Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Australia

Mar 01, 2025
pulisher
Mar 01, 2025

Century Therapeutics faces Nasdaq delisting over share price - Investing.com India

Mar 01, 2025
pulisher
Feb 28, 2025

Century Therapeutics Receives Nasdaq Notice For Bid Price Deficiency -February 28, 2025 at 04:20 pm EST - Marketscreener.com

Feb 28, 2025
pulisher
Feb 20, 2025

Century Therapeutics Executive Sells Shares to Cover Tax Obligations - TradingView

Feb 20, 2025
pulisher
Feb 20, 2025

Century Therapeutics CEO sells shares worth $27,179 - Investing.com

Feb 20, 2025
pulisher
Feb 20, 2025

Century Therapeutics CEO sells shares worth $27,179 By Investing.com - Investing.com UK

Feb 20, 2025
pulisher
Feb 19, 2025

Century Therapeutics Partners with Experts for New Trial on Autoimmune Diseases - MSN

Feb 19, 2025

Century Therapeutics Inc Azioni (IPSC) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
Capitalizzazione:     |  Volume (24 ore):